BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. DESIGN AND METHODS: The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen within prospective trials. The prospective multicenter studies considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced intensity conditioning regimen. RESULTS: The median age of the patients was 50 years (range, 34-62 years) and the median follow-up was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis, and patients had received a median of three lines of therapy before the reduced intensity conditioning allogeneic stem cell transplantation. At the time of transplantation, 14 patients were in complete remission, 16 in partial remission and 7 had refractory or progressive disease after salvage chemotherapy. The 4-year overall survival rates for patients in complete remission, partial remission, or with refractory or progressive disease were 71%, 48% and 29%, respectively (P=0.09), whereas the 4-year cumulative incidences of non-relapse mortality were 26% (95% CI, 11-61), 33% (95% CI, 16-68) and 71% (95% CI, 44-100), respectively. The incidence of relapse for the whole group was only 8% (95% CI, 2-23). CONCLUSIONS: We conclude that this strategy of reduced intensity conditioning allogeneic stem cell transplantation may be associated with significant non-relapse mortality in heavily pre-treated patients with follicular lymphoma, but a remarkably low relapse rate. Long-term survival is likely in patients without progressive or refractory disease at the time of transplantation.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. DESIGN AND METHODS: The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen within prospective trials. The prospective multicenter studies considered included 37 patients with follicular lymphoma who underwent allogeneic stem cell transplantation between 1998 and 2007 with a fludarabine plus melphalan-based reduced intensity conditioning regimen. RESULTS: The median age of the patients was 50 years (range, 34-62 years) and the median follow-up was 52 months (range, 0.6 to 113 months). Most patients (77%) had stage III-IV at diagnosis, and patients had received a median of three lines of therapy before the reduced intensity conditioning allogeneic stem cell transplantation. At the time of transplantation, 14 patients were in complete remission, 16 in partial remission and 7 had refractory or progressive disease after salvage chemotherapy. The 4-year overall survival rates for patients in complete remission, partial remission, or with refractory or progressive disease were 71%, 48% and 29%, respectively (P=0.09), whereas the 4-year cumulative incidences of non-relapse mortality were 26% (95% CI, 11-61), 33% (95% CI, 16-68) and 71% (95% CI, 44-100), respectively. The incidence of relapse for the whole group was only 8% (95% CI, 2-23). CONCLUSIONS: We conclude that this strategy of reduced intensity conditioning allogeneic stem cell transplantation may be associated with significant non-relapse mortality in heavily pre-treated patients with follicular lymphoma, but a remarkably low relapse rate. Long-term survival is likely in patients without progressive or refractory disease at the time of transplantation.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin Journal: Blood Date: 2001-12-15 Impact factor: 22.113
Authors: R Martino; M D Caballero; C Canals; J A Simón; C Solano; A Urbano-Ispízua; J Bargay; C Rayón; A Léon; J Sarrá; J Odriozola; J G Conde; J Sierra; J San Miguel Journal: Br J Haematol Date: 2001-12 Impact factor: 6.998
Authors: Issa F Khouri; Peter McLaughlin; Rima M Saliba; Chitra Hosing; Martin Korbling; Ming S Lee; L Jeffrey Medeiros; Luis Fayad; Felipe Samaniego; Amin Alousi; Paolo Anderlini; Daniel Couriel; Marcos de Lima; Sergio Giralt; Sattva S Neelapu; Naoto T Ueno; Barry I Samuels; Fredrick Hagemeister; Larry W Kwak; Richard E Champlin Journal: Blood Date: 2008-04-14 Impact factor: 22.113
Authors: Stephen P Robinson; Anthony H Goldstone; Stephen Mackinnon; Angelo Carella; Nigel Russell; Carmen Ruiz de Elvira; Goli Taghipour; Norbert Schmitz Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Andrew R Rezvani; Barry Storer; Michael Maris; Mohamed L Sorror; Edward Agura; Richard T Maziarz; James C Wade; Thomas Chauncey; Stephen J Forman; Thoralf Lange; Judith Shizuru; Amelia Langston; Michael A Pulsipher; Brenda M Sandmaier; Rainer Storb; David G Maloney Journal: J Clin Oncol Date: 2007-12-03 Impact factor: 44.544
Authors: Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport Journal: Biol Blood Marrow Transplant Date: 2010-11-10 Impact factor: 5.742
Authors: S Yano; T Mori; Y Kanda; J Kato; C Nakaseko; S Fujisawa; N Tomita; R Sakai; K Shono; T Saitoh; N Aotsuka; N Kobayashi; T Saito; S Takahashi; H Kanamori; S Okamoto Journal: Bone Marrow Transplant Date: 2015-07-13 Impact factor: 5.483
Authors: Anna Sureda; Mei-Jie Zhang; Peter Dreger; Jeanette Carreras; Timothy Fenske; Herve Finel; Harry Schouten; Silvia Montoto; Stephen Robinson; Sonali M Smith; Ariane Boumedil; Mehdi Hamadani; Marcelo C Pasquini Journal: Cancer Date: 2018-02-09 Impact factor: 6.860
Authors: Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger Journal: Bone Marrow Transplant Date: 2020-06-18 Impact factor: 5.483
Authors: M A Kharfan-Dabaja; N El-Jurdi; E Ayala; A S Kanate; B N Savani; M Hamadani Journal: Bone Marrow Transplant Date: 2017-04-03 Impact factor: 5.483
Authors: Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus M Kröger; Parameswaran N Hari; Kwang Woo Ahn; Jeanette Carreras; Veronika Bachanova; Asad Bashey; Jonathon B Cohen; Anita D'Souza; César O Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; Mohamed A Kharfan-Dabaja; Andreas Klein; Grace H Ku; Ginna G Laport; Hillard M Lazarus; Alan M Miller; Alberto Mussetti; Richard F Olsson; Shimon Slavin; Saad Z Usmani; Ravi Vij; William A Wood; David G Maloney; Anna M Sureda; Sonali M Smith; Mehdi Hamadani Journal: Biol Blood Marrow Transplant Date: 2015-08-04 Impact factor: 5.742
Authors: Timothy S Fenske; Mehdi Hamadani; Jonathon B Cohen; Luciano J Costa; Brad S Kahl; Andrew M Evens; Paul A Hamlin; Hillard M Lazarus; Effie Petersdorf; Christopher Bredeson Journal: Biol Blood Marrow Transplant Date: 2016-04-27 Impact factor: 5.742